The Morgan Welch Inflammatory Breast Cancer Research Program is committed to finding what causes inflammatory breast cancer and identifying new treatment options. We are conducting a number of treatment-based studies and a wide variety of lab based studies to understand this disease better.
Protocol 2006-1072: Inflammatory Breast Cancer (IBC) – N. Ueno
The goal of this research study is to collect blood and tissue samples, and clinical data from patients with a diagnosis of inflammatory breast cancer who either have never received treatment (Cohort 1) or have previously received treatment (Cohort 2) for IBC. Samples and information collected from patients with IBC are very precious and critical for the researchers to learn about the disease and to find the cure for the disease. The samples will be banked at MD Anderson Cancer Center and will be used for future critical IBC researches that have been or will be approved by the MDACC Institutional Review Board. Patients’ information and privacy are protected and maintained at all times.
For information about enrolling in clinical trials contact Jie Willey, MSN, 713-792-3965.
Neoadjuvant Therapies for IBC
2008-0372: Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients with Primary Inflammatory Breast Cancer (IBC) without HER2 Overexpression - N Ueno
HER- 2 positive:
NSABPFB-7: A Phase II randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2 Positive Breast Cancer - V Valero
Concurrent Adjuvant Therapy with Radiation
Inflammatory or Loco-regionally Recurrent Breast Cancer:
2012-0399: A Phase 1 Study of Veliparib Administered Concurrently with Chest Wall and Nodal Radiation Therapy in Patients with Inflammatory or Loco-regionally Recurrent Breast Cancer
Therapies for Metastatic IBC
2010-0296: A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients with First Local or Distant Relapse HER2-negative Inflammatory Breast Cancer (IBC) (up to 2 prior therapy). R Alvarez
Triple negative metastatic:
2010-0683: A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of metmab in combination with Paclitaxel in patients with metastatic, triple-negative breast cancer. V Valero (Closed to New Patient Entry)
HER2 positive metastatic :
2010-0842: Phase I/II Study of Entinostat and Lapatinib in Patients with HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab has Failed. N Ueno
No biomarker requirements metastatic:
2012-0510: A phase 1A/1B, multi-center, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the pleiotropic pathway modifier CC-122 administered orally to subjects with advanced solid tumors (Pending activation)
ALK positive metastatic:
2012-0142: A phase I, multicenter, open-label, dose escalation study of ASP3026 in subjects with advanced malignancies (pending activation)
Phase I Studies
MD Anderson has a program dedicated to the latest cutting edge therapies in testing. The Clinical Center for Targeted Therapy conducts innovative Phase I trials (early drug trials) with new drugs that may eventually improve the management of cancer. It doesn’t mean there are no other chemotherapies you can use, in fact, it's just the opposite! It usually means you are in good shape and might be a better candidate for one of the newer, more targeted therapies rather than traditional therapies.
Stem Cell Transplant
For a certain population of patients, after completing their initial therapy or have responding metastatic disease, stem cell transplant may be option with the goal to reduce the chance of recurrence.